Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Drug PIC

MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China

Fineline Cube Sep 4, 2026
Company Deals PIC

Typewriter Therapeutics Raises USD 56 Million Series A to Advance TPRT RNA Gene Insertion Platform for In Vivo CAR-T and Liver Diseases

Fineline Cube Sep 4, 2026
Company Deals Drug PIC

Takeda and Belief BioMed End Xinjiuning Commercialization Partnership; Belief BioMed to Advance Gene Therapy Independently

Fineline Cube Sep 4, 2026
Company Deals Drug PIC

Keymed Biosciences Grants Aeira Exclusive Rights to Stapokibart Across 18 Southeast and Central Asia Markets, Securing High Double‑Digit Royalties

Fineline Cube Sep 3, 2026
Company Deals PIC

Medtronic Invests USD 700 Million in Cornerstone Robotics, Wins Distribution Rights for Sentire Endoscopic Surgical Robot Outside the U.S.

Fineline Cube Sep 3, 2026
Company Drug PIC

MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China

Fineline Cube Sep 4, 2026
Company Drug PIC

MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China

Fineline Cube Sep 4, 2026
Policy / Regulatory

China’s 2026 NHSA Drug Negotiations Open Sept 5 with Parallel Commercial Insurance Innovative Drug Catalog Talks

Fineline Cube Sep 4, 2026
Company Drug

Jiangsu Hengrui Pharmaceuticals Secures NMPA Approvals for SHR-2106 and HRS-1893 Clinical Trials

Fineline Cube May 31, 2023

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has separately announced receiving clinical trial approvals...

Company Deals

Galvanize Therapeutics Partners with Energenx Medical for Greater China Expansion

Fineline Cube May 31, 2023

US-based Galvanize Therapeutics Inc. has revealed a licensing deal with Shanghai-based Energenx Medical Ltd, which...

Company Drug

AstraZeneca Launches Calquence in China for Mantle Cell Lymphoma Treatment

Fineline Cube May 30, 2023

UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has announced the official market launch of Calquence...

Company Deals

Kangtai Biological Partners with Indian Pharmaceutical Giant for 13-Valent Pneumonia Vaccine

Fineline Cube May 30, 2023

Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a leading Chinese biopharmaceutical company, has entered...

Company Deals

Medtronic Launches AiBLE Orthopedic Ecosystem and Partners with Allinmd Orthopedics in China

Fineline Cube May 30, 2023

US-based Medtronic Inc., (NYSE: MDT) has launched AiBLE, an innovative ecological ecosystem concept for orthopedics,...

Company Deals

TYK Medicines Partners with WuXi STA for Comprehensive CMC Services

Fineline Cube May 30, 2023

Shanghai-based TYK Medicines has announced a partnership with WuXi STA, a subsidiary of WuXi AppTec...

Company Deals

Beijing’s E-Health Now Secures Tens of Millions in Series B Financing

Fineline Cube May 30, 2023

E-Health Now, a comprehensive health management platform headquartered in Beijing, has reportedly raised tens of...

Company Deals

Boyi Biotech Secures Over RMB100 Million in Series A Financing Led by JOLMO

Fineline Cube May 30, 2023

Boyi Biotech, a prominent biological microspheres developer headquartered in Changzhou, has reportedly secured more than...

Company Deals

Mindray Partners with Vazyme Biotech to Develop Automated Infection Screening Solutions

Fineline Cube May 30, 2023

China-based medical device company Mindray (SHE: 300760) has entered into a partnership with fellow Chinese...

Company Drug

Hisun Pharmaceutical’s SHP2 Inhibitor HS336 Gets NMPA Clinical Trial Approval

Fineline Cube May 30, 2023

Zhejiang Hisun Pharmaceutical Co., Ltd (SHA: 600267), a China-based pharmaceutical company, has announced that it...

Policy / Regulatory

Hainan Boao Lecheng Introduces 319 Overseas Drugs and Devices, Reports Significant Growth

Fineline Cube May 30, 2023

The Hainan Boao Lecheng International Medical Tourism Pilot Zone has introduced 319 clinically urgently needed...

Company

Moderna Establishes USD 100 Million Subsidiary in Shanghai to Expand mRNA Technology

Fineline Cube May 29, 2023

US-based vaccine manufacturer Moderna (NASDAQ: MRNA) has registered a new subsidiary in the Minhang district...

Drug Policy / Regulatory

Hubei Leads National Volume-Based Procurement of Patented Traditional Chinese Medicines

Fineline Cube May 29, 2023

The Healthcare Security Administration (HSA) bureau of Hubei province has released a notification outlining plans...

Company Drug

Harbour Biomed’s Porustobart Combo Shows Promise in HCC Treatment, ASCO Presentation Reveals

Fineline Cube May 29, 2023

China-based Harbour Biomed (HKG: 2142) has announced the publication of results from a Phase Ib...

Company Drug

Ascentage Pharma’s Olverembatinib Earns Breakthrough Designation for SDH-Deficient GIST

Fineline Cube May 29, 2023

The China’s Center for Drug Evaluation (CDE) has granted breakthrough therapy designation (BTD) to olverembatinib,...

Company Drug

Abbisko Therapeutics Reports Positive Phase Ib Results for ABSK021 at ASCO

Fineline Cube May 29, 2023

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) is poised to announce positive results from...

Company Drug

Shanghai Yizhong’s Paclitaxel Micelles Data to be Presented at ASCO Annual Meeting

Fineline Cube May 29, 2023

Shanghai Yizhong Pharmaceutical Co., Ltd (SHA: 688091), a China-based pharmaceutical company, has announced that clinical...

Legal / IP

SAMR Imposes Penalties on Grand Pharma and WuHan Huihai for Monopoly Agreements

Fineline Cube May 29, 2023

The State Administration for Market Regulation (SAMR) has imposed administrative penalties on Grand Pharmaceutical Group...

Company Drug

Ascentage Pharma to Present Clinical Results of Four Oncology Drugs at Medical Conference

Fineline Cube May 29, 2023

Suzhou-based Ascentage Pharma (HKG: 6855) has announced its intention to present the clinical results of...

Deals Policy / Regulatory

Hainan Province and NHSA Partner to Enhance Medical Insurance Industry with Real-World Data

Fineline Cube May 26, 2023

The government of Hainan province has entered into a strategic partnership with the National Healthcare...

Posts pagination

1 … 571 572 573 … 716

Recent updates

  • MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China
  • China’s 2026 NHSA Drug Negotiations Open Sept 5 with Parallel Commercial Insurance Innovative Drug Catalog Talks
  • Trinomab’s Retavibart Wins NMPA Priority Approval as RSV Prevention Monoclonal Antibody Xinduotuo
  • Xuanzhu Biopharmaceutical Signs Thailand Commercial Agreement with Innobic and ZaoAn for Bireociclib
  • Betta’s Ensartinib Wins NMPA Approval for Third Indication as Adjuvant Therapy in ALK-Positive NSCLC
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug PIC

MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China

Policy / Regulatory

China’s 2026 NHSA Drug Negotiations Open Sept 5 with Parallel Commercial Insurance Innovative Drug Catalog Talks

Company Drug

Trinomab’s Retavibart Wins NMPA Priority Approval as RSV Prevention Monoclonal Antibody Xinduotuo

Company Deals

Xuanzhu Biopharmaceutical Signs Thailand Commercial Agreement with Innobic and ZaoAn for Bireociclib

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.